FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioterrorism
Aethlon Medical Announces Lassa Virus Research Program
March 15th, 2007
Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, announced that it executed a research collaboration with The Southwest Foundation for Biomedical Research (SFBR) to study the Aethlon Hemopurifier(R) as a potential treatment for Lassa Fever. Lassa Fever is classified a category "A" bioterror threat in the United States, and is an endemic viral condition in Africa. Category "A" bioterror threats are defined by The Centers for Disease Control and Prevention (CDC) as agents that pose a risk to national security; are easily disseminated or transmitted from person to person; result in high mortality rates; could cause public panic and social...
Source: FDA Law Weekly (2007-03-15)
|
